This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jamieson CH et al. (2003) Allogeneic hematopoietic cell transplantation for patients with high risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience. Exp Hematol 31: 981–986
Lee S et al. (2003) Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 102: 3068–3070
Thomas X et al. (2004) Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 22: 4075–4086
Coustan-Smith E et al. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96: 2691–2696
Hollerman A et al. (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 6: 533–542
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Forman, S. Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?. Nat Rev Clin Oncol 2, 18–19 (2005). https://doi.org/10.1038/ncponc0060
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0060